PrognomIQ, Inc. announced that it will issue 16,537,834 series C preferred shares at issue price of $3.06 per share for the gross proceeds $50,605,772.04 in funding on February 16, 2022. The shares carry non-cumulative dividend value of $0.1836 per annum per share. The shares will be convertible in common shares at a price of $3.06 per share.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
111.5 USD | +2.55% | -2.41% | +3.54% |
Apr. 18 | T. Rowe Price says 2018 Tesla pay aligned with investor interests | RE |
Apr. 18 | T Rowe Price Promotes Tim Chamberlain as Asia Pacific Regional Chief Operating Officer, Effective 1 May 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.54% | 24.94B | |
-6.37% | 113B | |
+15.50% | 62.84B | |
+2.13% | 59.88B | |
+9.82% | 42.75B | |
+10.94% | 42.22B | |
+17.95% | 33.83B | |
-3.81% | 22.47B | |
+3.41% | 19.13B | |
-1.00% | 17.09B |
- Stock Market
- Equities
- TROW Stock
- News T. Rowe Price Group Inc.
- PrognomIQ, Inc. announced that it expects to receive $50.605772 million in funding